75992-73-3

Upstream product

• 1032745-96-2 bis(oximino(2,4-dichlorophenyl)acetonitrile)platinum(II) dichloride 
• 67-68-5 dimethyl sulfoxide 
• 10025-65-7 platinum(II) chloride 
• 10025-99-7 potassium tetrachloroplatinate(II) 
• 120272-54-0 trans-{Pt(DMSO)(NMe₃)Cl₂} 
• 149840-82-4 {(dimethylsulfoxide)(chloro)(N,N'-di-n-butyldithiooxamidato)platinum(II)⁽¹⁺⁾,(Cl^(1-))} 
• 51425-32-2 trans-Pt(Me₂SO)(pyridine)Cl₂ 
• 15227-42-6 cis-dichlorobis(pyridine)platinum(II) 

Downstream Products

• 928625-35-8 PtCl₂C₁₂H₆N₂CN₂HC₆H₄N(CH₃)2 
• 928625-44-9 PtCl₂C₁₂H₆N₂CN₂HC₆H₄NO₂ 
• 70423-98-2 cis-dimethylbis[(sulfinyl-κS)bis[methane]]platinum(II) 
• 70423-99-3 cis-diphenylbis(dimethyl sulfoxide)platinum(II) 
• 13965-31-6 dichloro(2,2'-bipyridine)platinum(II) 
• 163365-19-3 [(C₆H₆)Ru((C₆H₅)2P(C₅H₄N))ClPt(OS(CH₃)2)Cl₂]⁽¹⁺⁾*Cl^(1-)=[(C₆H₆)Ru((C₆H₅)2P(C₅H₄N))Pt(OSC₂H₆)Cl₃]Cl 
• 148352-54-9 Pt(OS(CH₃)2)((C₆H₅)2P(C₅H₄N))Cl₂ 
• 332924-96-6 cis-dichlorobis[(1-cyclohexenyl)diphenylphosphine]platinum(II) 
• 332924-96-6 trans-dichlorobis[(1-cyclohexenyl)diphenylphosphine]platinum(II) 
• 265129-60-0 cis-(S-dimethylsulfoxide)(N,N-di(2-hydroxyethyl)-N'-(benzoyl)thioureato)chloroplatinum(II) 
• 165284-88-8 cis-bis(N,N-di(2-hydroxyethyl)-N'-(benzoyl)thioureato)platinum(II) 
• 302328-85-4 cis-(S-dimethylsulfoxide)(N-morpholino-N'-(benzoyl)thioureato)chloroplatinum(II) 
• 76850-77-6 cis-bis(N-morpholino-N'-(benzoyl)thioureato)platinum(II) 

Relevant academic research and scientific papers

Chelating and Bridging Roles of 2-(2-Pyridyl)benzimidazole and Bis(diphenylphosphino)acetylene in Stabilizing a Cyclic Tetranuclear Platinum(II) Complex

The reaction of complex [Pt(Me)(DMSO)(pbz)], 1, (pbz = 2-(2-pyridyl)benzimidazolate) with [PtMe(Cl)(DMSO)2], B, followed by addition of bis(diphenylphosphino)acetylene (dppac), gave the novel tetranuclear platinum complex [Pt4Me4(μ-dppac)2(pbz)2Cl2], 2, bearing both the pbz and dppac ligands. In this structure, the pbz ligands are both chelating and bridging to stabilize the tetraplatinum framework. The tetranuclear Pt(II) complex was fully characterized by NMR spectroscopy, X-ray crystallography, and mass spectrometry, and its electronic structure was investigated and supported by DFT calculations.

A cyclometalated trinuclear Ir(iii)/Pt(ii) complex as a luminescent probe for histidine-rich proteins

Organometallic complexes have important application in the field of protein staining, with potential for use in proteomic analysis. The rational synthesis of a trinuclear luminescent organometallic complex with two platinum(ii) centres appended to the cyclometalated ligand of the iridium(iii) centre is reported here. Two di-2-picolylamine groups bonded to the cyclometalated phenyl pyridine moiety provide three coordinating sites to each platinum centre. The replacement of chloride in the fourth coordination site of two square planar platinum metal centres with the imidazole nitrogen or sulphur atom of histidine/cysteine is evident from the change in luminescence intensity upon binding these amino acids. The increase in luminescence emission intensity upon binding of histidine to the organometallic complex allowed it to be used as a protein staining agent. Reversibility of staining upon washing with imidazole enhances the possibility of its application in mass spectrometric analysis.

Multinuclear magnetic resonance characterization and antiproliferative studies of novel dichlorido platinum(II) complexes containing kinetin riboside and 1-β-D-ribofuranosyl-4-(2-pyridyl)-1H-1,2,3-triazole

The chemical reaction between cis-[PtCl2(dmso)2] and kinetin riboside (KR) or 1-β-D-ribofuranosyl-4-(2-pyridyl)-1H-1,2,3-triazole (PTR) has resulted in two novel platinum(II) complexes being obtained with different compositions of the coordination sphere: cis-[PtCl2(PTR)] (1) and cis-[PtCl2(dmso)(KR)] (2). Based on multinuclear NMR results (1H, 13C, 15N, 195Pt), we have demonstrated that the N-donor ligands PTR and KR are able to coordinate to the Pt(II) ion as bidentate via two nitrogen atoms (N(3) and N(7)) or monodentate via only one nitrogen atom (N(7)), respectively. On the other hand, biological studies showed that the novel platinum(II) complexes exhibit different in vitro cytotoxicity towards A549 (lung carcinoma epithelial cells), T24 (urinary bladder cancer cells) and CRL1872 (malignant melanoma cells). The complex cis-[PtCl2(dmso)(KR)] (2) shows in vitro cytotoxicity against T24 and CRL1872 cell lines (the IC50 parameters amount to 52.2 μM and 21.4 μM, respectively), whereas cis-[PtCl2(PTR)] (1) is not able to inhibit a proliferation of these cells in the range of tested concentrations.

8-Mercaptoquinoline as a Ligand for Enhancing the Photocatalytic Activity of Pt(II) Coordination Complexes: Reactions and Mechanistic Insights

A family of quinoline-platinum(II) complexes as efficient photocatalysts is presented. Their key characteristic is their easy preparation by coordination of the readily available 8-hydroxy- or 8-thio-quinoline ligands, which are well known for their strong chelating ability to different metal ions. In the different photochemical transformations investigated, such as cross-dehydrogenative coupling, oxidation of arylboronic acids, and asymmetric alkylation of aldehydes, 8-mercaptoquinoline-Pt(II) complex proved to be the most general catalyst. Moreover, quenching experiments showed that, contrary to related methods reported in the literature, these complexes followed an oxidative quenching mechanism in all transformations studied. Besides, simulations performed with high-level ab initio methods of the complexes have helped to understand their photocatalytic activity.

Enhanced Catalytic Activity of (DMSO)2PtCl2 for the Methane Oxidation in the SO3-H2SO4 System

Among the various methane activation reactions, oleum-mediated (SO3-H2SO4) methane oxidation to methyl bisulfate (MBS), a methanol precursor, is one of the best methods in terms of methane conversion and product selectivity. In this report, we investigated the effect of the catalyst concentration on the MBS yield using the catalyst systems (bpym)PtCl2, K2PtCl4, and (DMSO)2PtCl2 at 180 °C for 3 h. (bpym)PtCl2 showed a very high stability as well as a high MBS yield of over 84%, but its catalytic activity expressed in terms of turnovers for 3 h was in the range 50-500. K2PtCl4 showed very high catalyst turnovers of over 17 000 at a low catalyst concentration; however, it deactivated rapidly to PtCl2 which prevents achieving a high MBS yield that was achieved by (bpym)PtCl2. However, (DMSO)2PtCl2 showed an enhanced catalytic performance for both the MBS yield and the turnovers. An MBS yield of over 84% with a selectivity of 94% was obtained at a catalyst concentration of 3.0 mM, and its turnovers reached over 19 000 at a low catalyst concentration. This higher catalytic performance of (DMSO)2PtCl2 compared to the other chloride-ligated Pt compounds is due to the DMSO ligand on the Pt, which increases the solubility of the Pt species in oleum. Furthermore, as the DFT study revealed, the low dissociation energy of DMSO from the Pt center can facilitate the coordination of methane on the Pt reaction center. Although (DMSO)2PtCl2 was deactivated to PtCl2 after the reaction like the other Pt compounds with the chloride ligand, it can be reactivated to some extent by adding DMSO.

α-Diimine homologues of cisplatin: synthesis, speciation in DMSO/water and cytotoxicity

The Pt(ii) α-diimine complexes [PtCl2{κ2N-(HCNR)2}] (R = C6H11, 1; 4-C6H10OH, 2; 4-C6H4CH3, 3; 4-C6H4OH, 4) and [PtCl2

CATALYST FOR PRODUCING METHANOL PRECURSOR, METHANOL PRECURSOR PRODUCED USING THE CATALYST AND METHANOL PRODUCED USING THE METHANOL PRECURSOR

Disclosed is a novel catalyst for producing a methanol precursor. The use of the catalyst enables the production of a methanol precursor and methanol with high efficiency under low temperature and low pressure conditions. Also disclosed are a methanol precursor produced using the catalyst and methanol produced using the methanol precursor.

Rollover Cyclometalated Bipyridine Platinum Complexes as Potent Anticancer Agents: Impact of the Ancillary Ligands on the Mode of Action

Platinum-based anticancer coordination compounds are widely used in the treatment of many tumor types, where they are very effective but also cause severe side effects. Organoplatinum compounds are significantly less investigated than the analogous coordination compounds. We report here rollover cyclometalated Pt compounds based on 2,2′-bipyridine which are demonstrated to be potent antitumor agents both in vitro and in vivo. Variation of the co-ligands on the Pt(2,2′-bipyridine) backbone resulted in the establishment of structure-activity relationships. They showed that the biological activity was in general inversely correlated with the reaction kinetics to biomolecules as shown for amino acids, proteins, and DNA. The less stable compounds caused higher reactivity with biomolecules and were shown to induce p53-dependent DNA damage. In contrast, the presence of bulky PTA and PPh3 ligands was demonstrated to cause lower reactivity and increased antineoplastic activity. Such compounds were devoid of DNA-damaging activity and induced ATF4, a component of the endoplasmic reticulum (ER) stress pathway. The lead complex inhibited tumor growth similar to oxaliplatin while showing no signs of toxicity in test mice. Therefore, we demonstrated that it is possible to fine-tune rollover-cyclometalated Pt(II) compounds to target different cancer pathways and be a means to overcome the side effects associated with cisplatin and analogous compounds in cancer chemotherapy.

Preparation and application of chiral platinum complex crystal

The invention provides a chiral platinum complex crystal. The chiral platinum complex crystal has a chemical formula (I) as described in the specification. A synthetic method for the chiral platinum complex crystal (I) comprises the following steps: weighing 0.2662 g of bis(4-(R)-isopropyl-4,5-dihydro-2-oxazolinyl)-acetonitrile zinc and dissolving bis(4-(R)-isopropyl-4,5-dihydro-2-oxazolinyl)-acetonitrile zinc in 30 mL of dichloromethane used as a solvent; then adding 0.3406 g of Pt(DMSO)2Cl2, carrying out a reaction at room temperature for 60 h and then stopping the reaction; carrying out filtering and adding dichloromethane, petroleum ether and absolute ethyl alcohol; and carrying out natural volatilization so as to obtain the novel single crystal of a platinum complex. The chiral platinum complex crystal (I) shows good catalysis performance when applied to the Henry reaction of ethyl pyruvate and to reaction of benzaldehyde and benzamide, and the conversion rates of ethyl pyruvate, benzaldehyde and benzamide are as high as 41%, 56% and 40%, respectively.

Preparation and compounding method for chiral silver complex crystal

The invention relates to a chiral silver complex crystal. A chemical formula thereof is shown as formula (I) as follows. A compounding method for the chiral silver complex crystal comprises the following steps: weighing 0.6529g of bi-(4-isopropyl-4,5-dihydro-2-oxazoline)-acetonitrile zinc; dissolving in 30mL of dichloromethane used as a solvent; adding 0.6625g of Pt(DMSO)2(NO3)2; reacting for 48 hours under room temperature and then stopping reaction; filtering; adding dichloromethane, petroleum ether and absolute ethyl alcohol; and naturally volatilizing, thereby acquiring a novel silver zinc complex monocrystal. The application of the chiral silver complex crystal (I) in Henry reaction of benzaldehyde and reaction of benzamide shows an excellent catalytic performance and the conversion rate thereof is respectively as high as 78% and 35%.